摘要
目的:比较应用改善病情抗风湿药物不同组合短期治疗活动性类风湿关节炎的疗效和安全性。方法:接受改善病情抗风湿药物单药或二联治疗的RA患者132例随访12周;改善病情抗风湿药物单药组31例和联合用药组101例。比较两组患者治疗后活动性和疗效评价指标,并记录不良反应。结果:采用联合治疗方案占76.52%。各二联治疗组ACR20改善率相近;联合用药组疾病活动性高于单药组。大多数患者耐受性好,不良反应发生率有差异,来氟米特联合甲氨蝶呤组最高。结论:RA大多采用改善病情抗风湿药物联合治疗,各种联合用药方案均安全有效;来氟米特联合甲氨蝶呤不良反应较多。
Objective：To compare the efficacy and safety of different combinations of disease- modifying anti-rheumatic drugs in the short-term treatment of 132 cases with RA treated by monotherapy or bigeminy was made for 12 weeks.The monotherapy group （ 1 cases ） of active rheumatoid arthritis.Methods：Follow-up therapy of disease-modifying antirheumatic drugs and the combined treatment group （ 101 cases ） Activity and efficacy evaluation indexes were compared between the two groups after treatment,and adverse reactions were recorded.Results：76.52% of the patients were treated with combined therapy.After 12 weeks,the ACR20 improvement rates of the bigeminy treatment groups were similar;the disease activities of the combination groups were higher than those of the single drug groups.Most patients had good tolerance and adverse event rates was different,with leflunomide combined with methotrexate being higher.Conclusion：RA was mostly treated with disease-modifying antirheumatic drugs and each combination was safe and effective,with leflunomide and methotrexate having a lot of adverse reactions
出处
《风湿病与关节炎》
2013年第7期19-21,34,共4页
Rheumatism and Arthritis
关键词
关节炎
类风湿
联合治疗
改善病情抗风湿药物
安全性
疗效
arthritis
rheumatoid
combined therapy
disease-modifying antirheumatic drug
safety
efficacy
